←
Tempus1,494 posts
Tempus avatar✓

Tempus ✓

@TempusAI

Tempus is a technology company leading the adoption of #AI to advance precision medicine.

◷ Joined October 2015▧ 1,093 Photos and videos
Tempus avatar
Tempus@TempusAI·21h

Applications are now open for The PRECISION Challenge, a national program opening our foundation model work to the broader research community, including computational biologists, bioinformaticians, biostatisticians, and data scientists. The PRECISION Challenge will provide selected participants with an unprecedented ecosystem of resources, combining direct financial funding with scientific and analytical infrastructure. Program recipients will gain structured access to our proprietary de-identified data library, alongside our suite of foundation models, agentic tooling, and compute capabilities in the Lens Workspaces environment. Detailed eligibility requirements are provided with each RFP. Apply now: tempus.co/4kkoHXW

1:06
Tempus avatar
Tempus@TempusAI·Nov 12

xM (NeXT Personal® Dx) is a key part of the patient care continuum, providing crucial information during surveillance and monitoring for early-stage disease and for IO treatment response monitoring for late-stage disease. Now available to support your clinical insights, Real-Time Variant Tracker™ is a supplemental part of xM (NeXT Personal® Dx) that tracks resistance and therapeutically targetable variants, including variants associated with NCCN guideline-recommended and FDA-approved therapies. Learn more: tempus.co/4iLchFR

0:10
ACRP - Assoc. of Clinical Research Profession avatar
⟳ Tempus retweeted
ACRP - Assoc. of Clinical Research Profession@ACRPDC·Nov 11

What if AI could cut trial-matching chart review from 25 minutes to just 3 while boosting enrollment? Join Chelsea Osterman, MD, next Wednesday at 12 PM ET to explore trial matching, EDC data transfer & automated tumor measurements. Enroll > bit.ly/4xc9jQA

1:00
Tempus avatar
Tempus@TempusAI·Nov 11

Our CEO and Founder @lefkofsky recently joined @MTSlive to discuss the evolving role of AI in clinical care as patients increasingly consult #GenAI tools with their own health data. Over the next 3 to 5 years, healthcare systems must equip physicians with the same caliber of advanced, intelligent technology to support clinical decision-making.

1:41
Tempus avatar
Tempus@TempusAI·Nov 11

Next week, Tempus will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society Annual Meeting (November 18–21). In rare diseases like sarcoma, small patient populations have historically created barriers to research. By leveraging our multimodal library, which includes real-world data from more than 45,000 patients across 615 rare and ultra-rare cancer types, our team is uncovering novel insights into rare mesenchymal tumors to advance precision oncology. Read the full announcement to learn more: tempus.co/4zKUQww #CTOS2026

Post attachment
Tempus avatar
Tempus@TempusAI·Nov 10

Lung cancer demands clarity at every stage—because every patient’s journey is unique. This #LungCancerAwarenessMonth, we honor the resilience of the lung cancer community. Tempus is proud to support patients and their care teams with comprehensive genomic profiling, guiding personalized treatment decisions from initial diagnosis to long-term monitoring. Learn more about our comprehensive portfolio for lung cancer patients: tempus.co/4sSoduh

Post attachment
Ambry Genetics avatar
⟳ Tempus retweeted
Ambry Genetics@AmbryGenetics·Nov 9

We can't wait to see you this week at #NSGC26! Visit Booth 1169 to explore how we’re delivering true diagnostic intelligence—from our comprehensive testing compendium and vast, representative databases driving equity at scale, to seamless EHR integration paired with lab-driven reanalysis. Find more information, including a list of our scientific posters here: hubs.ly/Q04DPD780

Post attachment
Tempus avatar
Tempus@TempusAI·Nov 5

Data professionals spend as much as 40% of their time searching for data rather than analyzing it. Tempus One now surfaces data model definitions, schema, and analytic best practices for faster analyses with fidelity. Learn more in a new article here: tempus.co/4inmwkV

Post attachment
Tempus avatar
Tempus@TempusAI·Nov 4

We're looking forward to next week's #AMP2026. Our team will be on-site showcasing our comprehensive genomic testing portfolio alongside our latest AI-powered digital pathology applications. Visit Booth #909 or attend our workshop on Nov. 11 to learn more. tempus.co/4BI2cSJ

Post attachment
Tempus avatar
Tempus@TempusAI·Nov 3

Listen in as our CEO and founder @lefkofsky recaps Q3 at Tempus ⬇️ Access the Q3 shareholder letter here: tempus.co/4zmfIdj

2:06
Tempus avatar
Tempus@TempusAI·Nov 2

Turning complex healthcare data into actionable insights requires scale, clinical validation, and deep industry collaboration. Explore some of our Q3 2026 milestones ➡️

Post attachmentPost attachmentPost attachmentPost attachment
Tempus avatar
Tempus@TempusAI·Oct 30

Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. By continuously transforming data into insights, Tempus is building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before. Learn more: tempus.co/4knQbvA

0:30
Tempus avatar
Tempus@TempusAI·Oct 27

This #BreastCancerAwarenessMonth, we recognize the millions of patients, families, and care teams navigating the complexities of breast cancer. Because no two journeys are the same, timely genomic insights are critical for guiding targeted therapies. Tempus xF+ delivers broad-panel liquid biopsy profiling from a single blood draw to detect ESR1 and other actionable alterations at progression or when tissue is limited. Now, that same sample provides rapid pharmacogenomic (PGx) insights for DPYD and UGT1A1 in just ~3–5 days—helping evaluate toxicity risks and guide dosing without needing an extra draw. Learn more about how xF+ supports personalized care decisions: tempus.co/3VZftWX

Post attachment
Tempus avatar
Tempus@TempusAI·Oct 26

We're onsite at #AMCPNexus sharing how real-world evidence can be leveraged to advance managed care pharmacy practice. Attend tomorrow's live session to hear Emilie Scherrer expand on findings from her abstract presentation, which suggest that the composite mortality variable is a reliable endpoint for real-world evidence analyses. More info: tempus.co/amcpnexus

Post attachment